Bile Acids as Emerging Players at the Intersection of Steatotic Liver Disease and Cardiovascular Diseases
Biomolecules · 2024
DOI: 10.3390/biom14070841 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2024. Verfasst von Josh Bilson und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK. Hauptthemen laut MEDLINE: Bile Acids and Salts, Cardiovascular Diseases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR BRC Southampton, NIHR BRC-Southampton.
Abstract (Originalsprache)
Affecting approximately 25% of the global population, steatotic liver disease (SLD) poses a significant health concern. SLD ranges from simple steatosis to metabolic dysfunction-associated steatohepatitis and fibrosis with a risk of severe liver complications such as cirrhosis and hepatocellular carcinoma. SLD is associated with obesity, atherogenic dyslipidaemia, and insulin resistance, increasing cardiovascular risks. As such, identifying SLD is vital for cardiovascular disease (CVD) prevention and treatment. Bile acids (BAs) have critical roles in lipid digestion and are signalling molecules regulating glucose and lipid metabolism and influencing gut microbiota balance. BAs have been identified as critical mediators in cardiovascular health, influencing vascular tone, cholesterol homeostasis, and inflammatory responses. The cardio-protective or harmful effects of BAs depend on their concentration and composition in circulation. The effects of certain BAs occur through the activation of a group of receptors, which reduce atherosclerosis and modulate cardiac functions. Thus, manipulating BA receptors could offer new avenues for treating not only liver diseases but also CVDs linked to metabolic dysfunctions. In conclusion, this review discusses the intricate interplay between BAs, metabolic pathways, and hepatic and extrahepatic diseases. We also highlight the necessity for further research to improve our understanding of how modifying BA characteristics affects or ameliorates disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK.
- National Institute for Health Research Southampton Biomedical Research Centre, University of Southampton, University Hospital Southampton National Health Service Foundation Trust, Southampton SO16 6YD, UK.
- Division of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
ORCID-Profile: Josh Bilson, Christopher D Byrne
Förderung
- NIHR BRC Southampton
- NIHR BRC-Southampton
Zitieren
APA
Bilson, J., Scorletti, E., Swann, J. R., & Byrne, C. D. (2024). Bile Acids as Emerging Players at the Intersection of Steatotic Liver Disease and Cardiovascular Diseases. Biomolecules. https://doi.org/10.3390/biom14070841
Vancouver
Bilson J, Scorletti E, Swann JR, Byrne CD. Bile Acids as Emerging Players at the Intersection of Steatotic Liver Disease and Cardiovascular Diseases. Biomolecules. 2024. doi:10.3390/biom14070841
BibTeX
@article{Bilson2024,
author = {Bilson, Josh and Scorletti, Eleonora and Swann, Jonathan R and Byrne, Christopher D},
title = {Bile Acids as Emerging Players at the Intersection of Steatotic Liver Disease and Cardiovascular Diseases},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14070841}
}
EUVIMED